CivicaScript, a nonprofit generic drug company, has launched insulin glargine-yfgn and ustekinumab-aauz, expanding its national portfolio of low-cost treatments.
The insulin product, which is interchangeable with Lantus, is available in prefilled pens for $45 per box of five pens to pharmacies, with a maximum recommended price of $55 for consumers, according to a Jan. 5 news release. The offering is the result of a manufacturing and supply partnership with Biocon Biologics announced in October. CivicaScript is distributing the insulin nationwide under its own label, with the CalRx brand used in California pharmacies.
Ustekinumab-aauz is a biosimilar to Stelara and is indicated for plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. A 12-week supply is available in two strengths: $985 for 90 milligrams and $575 for 45 milligrams.
CivicaScript said both therapies are offered under its transparent pricing model for pharmacies, health plans and pharmacy benefit managers. The nonprofit is a unit of Civica Rx, which was founded by U.S. health systems to address generic drug shortages and pricing concerns.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
